Skip to Content
Webinar Recording

PQI of Toripalimab: The First and Only FDA-Approved Treatment for Recurrent Locally Advanced or Metastatic Nasopharyngeal Carcinoma

Recorded on: January 29, 2025

Dive into the details of toripalimab-tpzi, the first and only FDA-approved treatment for recurrent, locally advanced, or metastatic nasopharyngeal carcinoma.

Dr. Hyunseok Kang and Dr. Shirin Khorashadi share essential insights for enhancing care, including the latest on efficacy, safety, and dosing.